Calcium-channel-blocker response in idiopathic pulmonary arterial hypertension
This article has no abstract so we have provided the first paragraph of the full text.
There is evidence that high-dose calcium-channel blockers can prolong survival in a minority of patients with idiopathic pulmonary arterial hypertension (IPAH). Only a small subset of patients show a sustained response to this therapy, however. Sitbon and colleagues have carried out a retrospective study to determine the proportion of IPAH patients who benefit from calcium-channel-blocker therapy, and to describe the clinical and hemodynamic features of these patients.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
